Trial Profile
A 24-month, Phase IIIb, Open-label, Single Arm, Multicenter Study Assessing the Efficacy and Safety of an Individualized, Stabilization-criteria-driven PRN Dosing Regimen With 0.5-mg Ranibizumab Intravitreal Injections Applied as Monotherapy in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Jul 2016
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Retinal oedema
- Focus Registrational; Therapeutic Use
- Acronyms CRYSTAL
- Sponsors Novartis
- 08 Oct 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 10 Apr 2015 New trial record